FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095529495> ?p ?o ?g. }

• W3095529495 endingPage "29188" @default.
• W3095529495 startingPage "29177" @default.
• W3095529495 abstract "Human monocytic cells in blood have important roles in host defense and express the enzyme carboxylesterase 1 (CES1). This metabolic serine hydrolase plays a critical role in the metabolism of many molecules, including lipid mediators called prostaglandin glyceryl esters (PG-Gs), which are formed during cyclooxygenase-mediated oxygenation of the endocannabinoid 2-arachidonoylglycerol. Some PG-Gs have been shown to exhibit anti-inflammatory effects; however, they are unstable compounds, and their hydrolytic breakdown generates pro-inflammatory prostaglandins. We hypothesized that by blocking the ability of CES1 to hydrolyze PG-Gs in monocytes/macrophages, the beneficial effects of anti-inflammatory prostaglandin D2-glyceryl ester (PGD2-G) could be augmented. The goals of this study were to determine whether PGD2-G is catabolized by CES1, evaluate the degree to which this metabolism is blocked by small-molecule inhibitors, and assess the immunomodulatory effects of PGD2-G in macrophages. A human monocytic cell line (THP-1 cells) was pretreated with increasing concentrations of known small-molecule inhibitors that block CES1 activity [chlorpyrifos oxon (CPO), WWL229, or WWL113], followed by incubation with PGD2-G (10 μM). Organic solvent extracts of the treated cells were analyzed by liquid chromatography with tandem mass spectrometry to assess levels of the hydrolysis product PGD2. Further, THP-1 monocytes with normal CES1 expression (control cells) and “knocked-down” CES1 expression (CES1KD cells) were employed to confirm CES1’s role in PGD2-G catabolism. We found that CES1 has a prominent role in PGD2-G hydrolysis in this cell line, accounting for about 50% of its hydrolytic metabolism, and that PGD2-G could be stabilized by the inclusion of CES1 inhibitors. The inhibitor potency followed the rank order: CPO > WWL113 > WWL229. THP-1 macrophages co-treated with WWL113 and PGD2-G prior to stimulation with lipopolysaccharide exhibited a more pronounced attenuation of pro-inflammatory cytokine levels (interleukin-6 and TNFα) than by PGD2-G treatment alone. In contrast, prostaglandin E2-glyceryl ester (PGE2-G) had opposite effects compared to those of PGD2-G, which appeared to be dependent on the hydrolysis of PGE2-G to PGE2. These results suggest that the anti-inflammatory effects induced by PGD2-G can be further augmented by inactivating CES1 activity with specific small-molecule inhibitors, while pro-inflammatory effects of PGE2-G are attenuated. Furthermore, PGD2-G (and/or its downstream metabolites) was shown to activate the lipid-sensing receptor PPARγ, resulting in altered “alternative macrophage activation” response to the Th2 cytokine interleukin-4. These findings suggest that inhibition of CES1 and other enzymes that regulate the levels of pro-resolving mediators such as PGD2-G in specific cellular niches might be a novel anti-inflammatory approach." @default.
• W3095529495 created "2020-11-09" @default.
• W3095529495 creator A5061598525 @default.
• W3095529495 creator A5063407875 @default.
• W3095529495 creator A5065360308 @default.
• W3095529495 creator A5080776198 @default.
• W3095529495 date "2020-11-03" @default.
• W3095529495 modified "2023-09-30" @default.
• W3095529495 title "Inactivation of CES1 Blocks Prostaglandin D₂ Glyceryl Ester Catabolism in Monocytes/Macrophages and Enhances Its Anti-inflammatory Effects, Whereas the Pro-inflammatory Effects of Prostaglandin E₂ Glyceryl Ester Are Attenuated" @default.
• W3095529495 cites W1491261527 @default.
• W3095529495 cites W1547123213 @default.
• W3095529495 cites W1871478581 @default.
• W3095529495 cites W1990144502 @default.
• W3095529495 cites W1996095828 @default.
• W3095529495 cites W2007402666 @default.
• W3095529495 cites W2019387110 @default.
• W3095529495 cites W2020014337 @default.
• W3095529495 cites W2033660869 @default.
• W3095529495 cites W2037202562 @default.
• W3095529495 cites W2037248257 @default.
• W3095529495 cites W2037644150 @default.
• W3095529495 cites W2049802647 @default.
• W3095529495 cites W2054472394 @default.
• W3095529495 cites W2086458197 @default.
• W3095529495 cites W2114570899 @default.
• W3095529495 cites W2141753787 @default.
• W3095529495 cites W2171752908 @default.
• W3095529495 cites W2278057954 @default.
• W3095529495 cites W2329884988 @default.
• W3095529495 cites W2545714555 @default.
• W3095529495 cites W2593024568 @default.
• W3095529495 cites W2616020608 @default.
• W3095529495 cites W2732879716 @default.
• W3095529495 cites W2784058110 @default.
• W3095529495 cites W2791806364 @default.
• W3095529495 cites W2796499147 @default.
• W3095529495 cites W2802488634 @default.
• W3095529495 cites W2825042034 @default.
• W3095529495 cites W2884052855 @default.
• W3095529495 cites W2903211914 @default.
• W3095529495 cites W2914709866 @default.
• W3095529495 cites W2975852739 @default.
• W3095529495 cites W2976636037 @default.
• W3095529495 cites W3000380130 @default.
• W3095529495 cites W86026435 @default.
• W3095529495 doi "https://doi.org/10.1021/acsomega.0c03961" @default.
• W3095529495 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7675540" @default.
• W3095529495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33225149" @default.
• W3095529495 hasPublicationYear "2020" @default.
• W3095529495 type Work @default.
• W3095529495 sameAs 3095529495 @default.
• W3095529495 citedByCount "6" @default.
• W3095529495 countsByYear W30955294952021 @default.
• W3095529495 countsByYear W30955294952022 @default.
• W3095529495 countsByYear W30955294952023 @default.
• W3095529495 crossrefType "journal-article" @default.
• W3095529495 hasAuthorship W3095529495A5061598525 @default.
• W3095529495 hasAuthorship W3095529495A5063407875 @default.
• W3095529495 hasAuthorship W3095529495A5065360308 @default.
• W3095529495 hasAuthorship W3095529495A5080776198 @default.
• W3095529495 hasBestOaLocation W30955294951 @default.
• W3095529495 hasConcept C170493617 @default.
• W3095529495 hasConcept C185592680 @default.
• W3095529495 hasConcept C203014093 @default.
• W3095529495 hasConcept C2776914184 @default.
• W3095529495 hasConcept C2777198256 @default.
• W3095529495 hasConcept C2777361909 @default.
• W3095529495 hasConcept C2780664492 @default.
• W3095529495 hasConcept C2781184567 @default.
• W3095529495 hasConcept C46721173 @default.
• W3095529495 hasConcept C55493867 @default.
• W3095529495 hasConcept C62231903 @default.
• W3095529495 hasConcept C8051207 @default.
• W3095529495 hasConcept C86803240 @default.
• W3095529495 hasConcept C96942376 @default.
• W3095529495 hasConcept C98274493 @default.
• W3095529495 hasConceptScore W3095529495C170493617 @default.
• W3095529495 hasConceptScore W3095529495C185592680 @default.
• W3095529495 hasConceptScore W3095529495C203014093 @default.
• W3095529495 hasConceptScore W3095529495C2776914184 @default.
• W3095529495 hasConceptScore W3095529495C2777198256 @default.
• W3095529495 hasConceptScore W3095529495C2777361909 @default.
• W3095529495 hasConceptScore W3095529495C2780664492 @default.
• W3095529495 hasConceptScore W3095529495C2781184567 @default.
• W3095529495 hasConceptScore W3095529495C46721173 @default.
• W3095529495 hasConceptScore W3095529495C55493867 @default.
• W3095529495 hasConceptScore W3095529495C62231903 @default.
• W3095529495 hasConceptScore W3095529495C8051207 @default.
• W3095529495 hasConceptScore W3095529495C86803240 @default.
• W3095529495 hasConceptScore W3095529495C96942376 @default.
• W3095529495 hasConceptScore W3095529495C98274493 @default.
• W3095529495 hasFunder F4320337354 @default.
• W3095529495 hasIssue "45" @default.
• W3095529495 hasLocation W30955294951 @default.
• W3095529495 hasLocation W30955294952 @default.
• W3095529495 hasLocation W30955294953 @default.
• W3095529495 hasLocation W30955294954 @default.
• W3095529495 hasOpenAccess W3095529495 @default.

• next